EAM Investors’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

EAM Investors’s Portfolio BHVN Stock Details BHVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-12,216	Closed	-$1.45M	–	394
2022 Q1	$1.45M	Buy	+12,216	New	+$1.52M	0.27%	180
2021 Q4	–	Sell	-21,989	Closed	-$3.05M	–	412
2021 Q3	$3.05M	Sell	21,989 -2,059	-9%	-$257K	0.52%	49
2021 Q2	$2.33M	Buy	24,048 +16,762	+230%	+$1.36M	0.36%	83
2021 Q1	$498K	Sell	7,286 -8,161	-53%	-$660K	0.08%	320
2020 Q4	$1.32M	Sell	15,447 -305	-2%	-$25.8K	0.22%	222
2020 Q3	$1.02M	Sell	15,752 -13,633	-46%	-$893K	0.24%	200
2020 Q2	$2.15M	Buy	+29,385	New	+$1.56M	0.47%	68
2019 Q3	–	Sell	-59,383	Closed	-$2.6M	–	337
2019 Q2	$2.6M	Sell	59,383 -2,453	-4%	-$138K	0.64%	38
2019 Q1	$3.18M	Buy	+61,836	New	+$2.67M	0.78%	16

Other funds holding BHVN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EAM Investors's BHVN Position: Q2 2022 in Review

EAM Investors sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q2 2022, closing a stake of 12,216 shares — an estimated $1.45M sold.

EAM Investors first reported a position in BHVN in Q1 2019 and held it in 9 quarters. The position peaked at $3.18M in Q1 2019. 329 funds tracked by Wall St. Rank hold BHVN as of Q2 2022.

EAM Investors reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q2 2022 after selling out during the quarter.
EAM Investors sold 12,216 Biohaven Pharmaceutical Holding Company Ltd. shares in Q2 2022, an estimated $1.45M.
EAM Investors first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q1 2019 and held it in 9 quarters.
EAM Investors's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $3.18M in Q1 2019.
329 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q2 2022.

Based on EAM Investors's 13F filing for Q2 2022, filed 12 Aug 2022.